

Corp. Off.: 502, Kanakia Atrium - 2,  
Next to Courtyard Marriott Hotel,  
Andheri Kurla Road, Andheri (East),  
Mumbai - 400 093 (India)  
Ph.: + 91 22 61933100 Fax : +91 22 61933114

12<sup>th</sup> February, 2016

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001

**National Stock exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051

**Kind Attn: General Manager-DCS**

corp.relations@bseindia.com

**Kind Attn: Head- Listing**

cmlist@nse.co.in

**Sub: Intimation under Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015- Outcome of Board Meeting held on 12<sup>th</sup> February, 2016 regarding approval of Unaudited Financial Results for 3<sup>rd</sup> quarter ended 31<sup>st</sup> December, 2015**

Dear Sirs,

This has in reference to the regulation mentioned above:

We hereby inform you that the Board of Directors at its meeting held today has, inter alia, approved the Unaudited Financial Results of the Company for the 3<sup>rd</sup> quarter ended 31<sup>st</sup> December, 2015. The Audit Committee reviewed the Unaudited Financial Results at its meeting held earlier today which have been subjected to a limited review by the Statutory Auditors. The Statement of Unaudited Financial Results, together with the Limited Review Report is attached.

This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**



(Rajesh Mahajan)

Managing Director

DIN No. 02000634


Encl.: As Stated Above

**SGCO & Co.**  
Chartered Accountants

**The Board of Directors**  
**Brooks Laboratories Limited**

1. We have reviewed the statement of unaudited financial results (the "Statement") of **Brooks Laboratories Limited** (the "Company"), for the quarter ended on December 31, 2015. The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulation, 2015"). This Statement is the responsibility of the Company's management and has been approved by the board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S G C O & Co.**  
Chartered Accountants  
Firm Reg. No : 112081W

  
**Suresh Murarka**  
Partner  
Mem No.: 44739



Place: Mumbai  
Date: 12<sup>th</sup> February, 2016

4A, Kaledonia-HDIL,  
2<sup>nd</sup> Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069. India

Tel.: +91 22 6625 6363  
Fax: +91 22 6625 6364  
E-mail: info@sgco.co.in  
www.sgco.co.in



**BROOKS LABORATORIES LIMITED**

CIN NO: L24232HP2002PLC000267

Tel No : +91 1795 654001/02/03, Fax No : +91 1795 236939, E-mail : investors@brookslabs.net, Website: www.brookslabs.net

Unaudited Financial Results for the Quarter and Nine Month Ended December 31, 2015

PART I

(Rs. In lacs)

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31.12.2015	30.09.2015	31.12.2014	31.12.2015	31.12.2014	31.03.2015
	(Unaudited)			(Unaudited)		(Audited)
<b>1 Income from operations</b>						
(a) Net sales (Net of excise duty)	2,086.73	2,047.17	2,368.19	5,931.60	6,169.91	8,521.33
<b>Total income from operations (net)</b>	<b>2,086.73</b>	<b>2,047.17</b>	<b>2,368.19</b>	<b>5,931.60</b>	<b>6,169.91</b>	<b>8,521.33</b>
<b>2 Expenses</b>						
(a) Cost of materials consumed	1,390.12	1,361.99	1,651.41	4,011.12	4,371.48	6,041.14
(b) Changes in inventories of finished goods & work-in-progress	(16.93)	(7.75)	22.06	4.91	48.84	23.61
(c) Employee benefits expense	185.38	187.18	124.04	503.60	353.01	474.67
(d) Depreciation and amortization expense	30.28	28.53	23.28	86.85	83.93	110.36
(e) Other Expenses	224.91	239.01	364.24	678.52	925.48	1,295.80
<b>Total expenses</b>	<b>1,813.76</b>	<b>1,808.96</b>	<b>2,185.03</b>	<b>5,285.00</b>	<b>5,782.74</b>	<b>7,945.59</b>
<b>3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>272.97</b>	<b>238.21</b>	<b>183.16</b>	<b>646.60</b>	<b>387.17</b>	<b>575.74</b>
4 Other income	53.65	44.28	68.38	134.35	199.25	225.17
<b>5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>326.62</b>	<b>282.49</b>	<b>251.54</b>	<b>780.95</b>	<b>586.42</b>	<b>800.91</b>
6 Finance costs	35.69	26.73	25.99	69.28	33.18	44.34
<b>7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 - 6)</b>	<b>290.93</b>	<b>255.76</b>	<b>225.55</b>	<b>711.67</b>	<b>553.25</b>	<b>756.57</b>
8 Exceptional items / Prior period items	-	-	0.00	-	(210.18)	278.47
<b>9 Profit / (Loss) from ordinary activities before tax (7 - 8)</b>	<b>290.93</b>	<b>255.76</b>	<b>225.55</b>	<b>711.67</b>	<b>763.42</b>	<b>1,035.04</b>
10 Tax expense (Refer Note 2)	11.47	85.60	46.78	110.68	50.93	88.32
<b>11 Net Profit / (Loss) from ordinary activities after tax (9-10)</b>	<b>279.46</b>	<b>170.16</b>	<b>178.77</b>	<b>600.99</b>	<b>712.49</b>	<b>946.72</b>
12 Extraordinary items	-	-	-	-	-	-
<b>13 Net Profit / (Loss) for the period (11 + 12)</b>	<b>279.46</b>	<b>170.16</b>	<b>178.77</b>	<b>600.99</b>	<b>712.49</b>	<b>946.72</b>
14 Paid-up equity share capital (Face Value Rs.10/- per share)	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64	1,618.64
15 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	9,523.04
<b>16.i Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):</b>						
(a) Basic -in Rs.	1.73	1.05	1.10	3.71	4.40	5.85
(b) Diluted- in Rs.	1.73	1.05	1.10	3.71	4.40	5.85
<b>16.ii Earnings per share (after extraordinary items) (of Rs.10/- each) (not annualised):</b>						
(a) Basic -in Rs.	1.73	1.05	1.10	3.71	4.40	5.85
(b) Diluted- in Rs.	1.73	1.05	1.10	3.71	4.40	5.85

Notes :

- The above results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th February, 2016.
- Tax expense includes Current Tax, Mat Credit Entitlement, Deferred Tax & Taxes for earlier years. Tax expense of Nine Month ended & for Quarter ended 30th September 2015 includes Rs 70.47 lacs for taxes of earlier Years.
- The Company is mainly engaged in the business of "Pharmaceutical Formulations" and there is no other reportable business segment as per Accounting Standard (AS-17).
- Figures of the previous period / year have been reclassified / regrouped wherever necessary.

Date : February 12, 2016  
Place : Mumbai

For and on behalf of the Board

Rajesh Mahajan  
DIN No. : 02000634  
Managing Director

